title: Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab.
authors.affiliation: Neurology Department, IRCCS Don C. Gnocchi Foundation, Milano, Italy. mgironi@dongnocchi.it
authors.forename: Maira
authors.initials: M
authors.lastname: Gironi
authors.forename: M
authors.initials: M
authors.lastname: Saresella
authors.forename: L
authors.initials: L
authors.lastname: Ceresa
authors.forename: M
authors.initials: M
authors.lastname: Calvo
authors.forename: P
authors.initials: P
authors.lastname: Ferrante
authors.forename: F
authors.initials: F
authors.lastname: Merli
authors.forename: R
authors.initials: R
authors.lastname: Nemni
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000097:blood; D015704:CD4 Antigens / Q000097:blood; D016827:CD8 Antigens / Q000097:blood; D018450:Disease Progression; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects; D018950:Lipopolysaccharide Receptors / Q000097:blood; D008875:Middle Aged; D009422:Nervous System Diseases / Q000150:complications / Q000276:immunology; D000069283:Rituximab; D008258:Waldenstrom Macroglobulinemia / Q000150:complications / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D015704:CD4 Antigens; D016827:CD8 Antigens; D007155:Immunologic Factors; D018950:Lipopolysaccharide Receptors; D000069283:Rituximab